Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Summit Therapeutics (SMMT) Other Operating Expenses: 2016-2024

Historic Other Operating Expenses for Summit Therapeutics (SMMT) over the last 1 years, with Dec 2024 value amounting to $205,000.

  • Summit Therapeutics' Other Operating Expenses rose 14.53% to $205,000 in Q4 2024 from the same period last year, while for Dec 2024 it was $15.1 million, marking a year-over-year increase of 114.90%. This contributed to the annual value of $313,000 for FY2024, which is 68.73% down from last year.
  • As of Q4 2024, Summit Therapeutics' Other Operating Expenses stood at $205,000, which was up 177.65% from -$264,000 recorded in Q3 2024.
  • In the past 5 years, Summit Therapeutics' Other Operating Expenses ranged from a high of $15.0 million in Q2 2024 and a low of -$264,000 during Q3 2024.
  • Moreover, its 3-year median value for Other Operating Expenses was $265,000 (2023), whereas its average is $3.1 million.
  • Data for Summit Therapeutics' Other Operating Expenses shows a peak YoY increase of 14.53% (in 2024) and a maximum YoY decrease of 199.62% (in 2024) over the last 5 years.
  • Summit Therapeutics' Other Operating Expenses (Quarterly) stood at $1.1 million in 2022, then crashed by 84.20% to $179,000 in 2023, then climbed by 14.53% to $205,000 in 2024.
  • Its last three reported values are $205,000 in Q4 2024, -$264,000 for Q3 2024, and $15.0 million during Q2 2024.